It has been reported that bortezomib, a first-generation proteasome inhibitor, could regulate the tumor microenvironment of head and neck cancer by recruiting tumor infiltrating immunocytes including CD4+/CD8+ T cells, B cells, macrophages and NK cells (Benvenuto et al., 2021). This evidence concerns the gene CD4 and neoplasm.